全文获取类型
收费全文 | 3210307篇 |
免费 | 257362篇 |
国内免费 | 9325篇 |
专业分类
耳鼻咽喉 | 45266篇 |
儿科学 | 100874篇 |
妇产科学 | 86442篇 |
基础医学 | 446433篇 |
口腔科学 | 91969篇 |
临床医学 | 293501篇 |
内科学 | 634685篇 |
皮肤病学 | 69687篇 |
神经病学 | 269619篇 |
特种医学 | 129031篇 |
外国民族医学 | 1111篇 |
外科学 | 489551篇 |
综合类 | 76909篇 |
现状与发展 | 3篇 |
一般理论 | 1299篇 |
预防医学 | 262244篇 |
眼科学 | 73600篇 |
药学 | 233624篇 |
9篇 | |
中国医学 | 5772篇 |
肿瘤学 | 165365篇 |
出版年
2018年 | 32855篇 |
2016年 | 29201篇 |
2015年 | 32879篇 |
2014年 | 46823篇 |
2013年 | 71055篇 |
2012年 | 92198篇 |
2011年 | 98210篇 |
2010年 | 59251篇 |
2009年 | 57108篇 |
2008年 | 92724篇 |
2007年 | 98764篇 |
2006年 | 99871篇 |
2005年 | 97299篇 |
2004年 | 93381篇 |
2003年 | 90472篇 |
2002年 | 88096篇 |
2001年 | 147396篇 |
2000年 | 152379篇 |
1999年 | 128297篇 |
1998年 | 38628篇 |
1997年 | 34847篇 |
1996年 | 35161篇 |
1995年 | 34630篇 |
1994年 | 32459篇 |
1993年 | 30393篇 |
1992年 | 104889篇 |
1991年 | 101661篇 |
1990年 | 98089篇 |
1989年 | 93968篇 |
1988年 | 87450篇 |
1987年 | 86239篇 |
1986年 | 81618篇 |
1985年 | 78438篇 |
1984年 | 59783篇 |
1983年 | 50945篇 |
1982年 | 31499篇 |
1981年 | 28339篇 |
1980年 | 26664篇 |
1979年 | 55684篇 |
1978年 | 39817篇 |
1977年 | 33539篇 |
1976年 | 31337篇 |
1975年 | 32896篇 |
1974年 | 40088篇 |
1973年 | 38182篇 |
1972年 | 35710篇 |
1971年 | 33090篇 |
1970年 | 30918篇 |
1969年 | 28790篇 |
1968年 | 26485篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Lalia Y. Ibrahim Krank P. DiFilippo Geremy E. Steed Manuel D. Cerqueira 《Journal of nuclear cardiology》2006,13(6):855-866
Conclusion Several quality-control measures take place before (patient and camera preparation) and during SPECT acquisition to achieve
high-quality images. Not uncommonly, technologists and physicians are left with suboptimal images that have to be addressed
to reach the “right answer” for patient diagnosis and hence management. In many cases patients may be reimaged, especially
if the problem is detected early, but in other cases either the patient has left the nuclear laboratory or there is an inevitable
problem that, even with reimaging, will not be resolved. In these situations the technologist and physician have to seek the
available techniques to obtain the best images possible. These resources are discussed in this issue as an aid in quality
control to obtain the best possible images. 相似文献
32.
D B Irving J L Cook H B Menz 《Journal of Science and Medicine in Sport》2006,9(1-2):11-22; discussion 23-4
33.
Peter G. Danias Thomas H. Hauser George Katsimaglis Rene M. Botnar Warren J. Manning 《Herz》2003,15(4):90-98
Coronary magnetic resonance angiography (CMRA) is a technique in clinical evolution. Current clinical applications include assessment for coronary anomalies, aneurysms, bypass graft patency, and, in experienced centers, the exclusion of proximal and multivessel coronary artery disease (CAD). As local expertise increases and more extensive multicenter data become available, additional applications will be established. CMRA promises to supplement and in some cases obviate the need for X-ray contrast angiography, and to expand our understanding of the pathophysiology of CAD. Zusammenfassung Die Magnetresonanzangiographie der Koronargefäße (CMRA) ist eine sich ständig weiterentwickelnde Technik. Etablierte Anwendungen sind zurzeit die Beurteilung von koronaren Anomalien, Aneurysmen und der Durchgängigkeit von Bypasses. Auch der Ausschluss proximaler Koronarstenosen und einer koronaren Mehrgefäßerkrankung ist in einigen spezialisierten Zentren möglich. Mit zunehmender Erfahrung der jeweiligen Anwender und der Verfügbarkeit von Ergebnissen großer multizentrischer Studien können zukünftig weitere klinische Anwendungen etabliert werden. In der Zukunft könnte die CMRA ergänzende Informationen zur Indikationsstellung einer konventionellen Röntgenangiographie bringen und in einigen Fällen diese Untersuchung sogar ersetzen. Die CMRA wird unseren Einblick in die Pathophysiologie der koronaren Herzerkrankung sicher erweitern. 相似文献
34.
A-C Koschker M Fassnacht S Hahner D Weismann B Allolio 《Experimental and clinical endocrinology & diabetes》2006,114(2):45-51
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis. Patients present with signs of steroid hormone excess (e.g., Cushing's syndrome) or symptoms due to an abdominal mass. DIAGNOSIS: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up. The imaging of choice is CT or MRI with MRI being of additional use when invasion of big vessels is suspected. Apart from that, the use of 18-FDG-PET is becoming increasingly established. TREATMENT: Surgical resection is the therapeutic option of choice in stages 1 - 3. In stage 4, the adrenolytic compound mitotane is part of the first-line treatment, but often needs to be combined with cytotoxic chemotherapy. Most patients will eventually have a recurrence, so adjuvant treatment (mitotane/tumour bed radiation) has to be considered in high risk patients, even if randomized controlled trials on adjuvant treatment are still lacking. STRUCTURAL PROGRESS: Several national and European structures have recently been established in order to increase our knowledge of ACC, improve therapeutic options and diagnostic procedures, and promote research. GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies. ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking. Since 2003, patients can be enrolled in the German ACC Registry. France and Italy have also developed a central registry to collect nationwide data from patients with ACC. For the first time, patients with metastatic/unresectable ACC can participate in a prospective controlled randomized trial comparing two different cytotoxic chemotherapy regimes (FIRM-ACT). 相似文献
35.
B Dederichs M Dietlein B Jenniches-Kloth M Schmidt P Theissen D Moka H Schicha 《Experimental and clinical endocrinology & diabetes》2006,114(7):366-370
BACKGROUND: Radioiodine therapy (RIT) combined with glucocorticoids is an effective therapy for Graves' disease, but it is debatable whether glucocorticoids should be applied in patients without Graves' ophthalmopathy (GO). METHODS: The effect of 0.4 - 0.5 mg prednisone every second day over a period of 5 weeks after RIT was monitored over a follow-up period of at least 12 months after RIT. A questionnaire was sent to 186 consecutive patients without GO concerning eye symptoms after RIT. 148 patients (80 %) answered. If eye symptoms had occurred after RIT, additional clinical examination was carried out at our outpatient clinic. The primary endpoint was the absence or onset of GO within the first year after RIT. RESULTS: Within 12 months after RIT the examination confirmed GO in 5 out of 148 patients (3.4 %). In all cases the symptoms were transient. No adverse reaction to the use of prednisone after RIT was noted. CONCLUSIONS: The risk of new GO in the first year after RIT was low and the clinical course of GO was mild when RIT was combined with a low-dose glucocorticoid regimen. Preventive administration of glucocorticoids can therefore be recommended in patients with Graves' disease even without evident GO. 相似文献
36.
A I D'hulst K R Bracke T Maes J L De Bleecker R A Pauwels G F Joos G G Brusselle 《The European respiratory journal》2006,28(1):102-112
Chronic obstructive pulmonary disease (COPD) is characterised by a local pulmonary inflammatory response to respiratory pollutants and by systemic inflammation. Tumour necrosis factor (TNF)-alpha has been implicated in systemic effects of COPD and operates by binding the p55 (R1) and p75 (R2) TNF-alpha receptors. To investigate the contribution of each TNF-alpha receptor in the pathogenesis of COPD, the present study examined the effects of chronic air or cigarette smoke (CS) exposure in TNF-alpha R1 knockout (KO) mice, TNF-alpha R2 KO mice and wild type (WT) mice. CS was found to significantly increase the protein levels of soluble TNF-alpha R1 (by four-fold) and TNF-alpha R2 (by 10-fold) in the bronchoalveolar lavage of WT mice. After 3 months, CS induced a prominent pulmonary inflammatory cell influx in WT and TNF-alpha R1 KO mice. In TNF-alpha R2 KO mice, CS-induced pulmonary inflammation was clearly attenuated. After 6 months, no emphysema was observed in CS-exposed TNF-alpha R2 KO mice in contrast to WT and TNF-alpha R1 KO mice. CS-exposed WT and TNF-alpha R1 KO mice failed to gain weight, whereas the body mass of TNF-alpha R2 KO mice was not affected. These current findings suggest that both tumour necrosis factor-alpha receptors contribute to the pathogenesis of chronic obstructive pulmonary disease, but tumour necrosis factor-alpha receptor-2 is the most active receptor in the development of inflammation, emphysema and systemic weight loss in this murine model of chronic obstructive pulmonary disease. 相似文献
37.
38.
39.
S. Spinty H. Rogozinski G. T. Lealman J. E. Wraith 《Journal of inherited metabolic disease》2003,25(8):697-698
Summary: A female patient with isovaleric acidaemia had a successful outcome from pregnancy. 相似文献
40.